Conference abstractPublished 5 Aug 2013
Fullerenol C60 as a new therapeutic nanomedicine for inflammatory bowel disease
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Inflammatory bowel disease (IBD) is intractable disease that shows unexplained inflammation in the gastrointestinal tract. Although diverse therapeutic drugs such as 5-aminosalicylic acid (5-ASA) and N-acetyl-L-cysteine (NAC) were used, there were some problems with adverse effects and unresponsiveness. Therefore, it is expected to develop novel medicines. In this regard, we have focused on Fullerene C 60 , which is one of the most promising nanomaterials because of their antioxidant effect. We previously demonstrated that C 60 (OH) 36 , which is water-soluble fullerenol C 60 , have strong anti-oxidative and anti- inflammatory effects in vitro. Here, we evaluated the efficacy of C 60 (OH) 36 as a new therapeutic nanomedicine (~1 nm) for IBD. We examined the effects of C 60 (OH) 36 on IBD in animal model of dextran sulfate sodium (DSS). The DSS-induced colitis model has been extensively used because it shows similar symptoms compared to human colitis. Myeloperoxidase (MPO) activity is an index of acute inflammatory reaction with neutrophil infiltration into the colon. Therefore, we measured the levels of MPO activity in mice. MPO activity in C 60 (OH) 36 -treated and 5-ASA-treated mice were significantly decreased on the day 7 after DSS administration compared to that in distilled water-treated mice. These results indicated that C 60 (OH) 36 had a potential to be useful therapeutic nanomedicine for acute DSS experimental colitis. We expect that our studies might provide useful information for creating innovative nanomedicine for IBD.
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalTranslational Medicine
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Kazuma Higashisaka”
